3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物 （bsADC） SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心 （CDE） 批准，用于治疗晚期实体瘤。
公告指出，这是公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的行业领军者之一，公司已建立起坚实的领先优势。
与此同时，公司着眼于肿瘤治疗的迭代升级，持续拓展创新布局，构建了涵盖放射性核素偶联药物 (RDC)、bsADC 等前沿疗法的多元化管线矩阵，全力推动肿瘤现有治疗模式的突破与革新。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.